Login / Signup

Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.

Ganji Purnachandra NagarajuBatoul FarranMatthew FarrenGayathri ChalikondaChristina WuGregory B LesinskiBassel F El-Rayes
Published in: Cancer (2020)
Napabucasin is a radiosensitizer with a novel mechanism of action: increasing ROS production and inhibiting angiogenesis. Clinical trials testing the addition of napabucasin to chemoradiotherapy in rectal cancer are needed.
Keyphrases
  • rectal cancer
  • locally advanced
  • clinical trial
  • endothelial cells
  • signaling pathway
  • cell death
  • dna damage
  • vascular endothelial growth factor
  • squamous cell carcinoma
  • phase ii
  • double blind